Literature DB >> 19070928

Treatment failure in hepatitis C: mechanisms of non-response.

Andrew W Tai1, Raymond T Chung.   

Abstract

Hepatitis C virus (HCV) has evolved remarkable mechanisms that favor viral persistence by interfering with host innate and adaptive immune responses. These same mechanisms are likely to contribute to resistance to exogenously administered interferon used for HCV treatment. We review the host innate and adaptive immune responses in the context of HCV infection as well as the strategies by which these responses are subverted by the virus. In addition, the contribution of host factors, such as race and insulin resistance, to interferon non-responsiveness is discussed. Our progress in understanding the molecular underpinnings of interferon treatment failure in HCV infection has resulted in several promising and novel treatment strategies for HCV treatment non-responders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19070928      PMCID: PMC2743341          DOI: 10.1016/j.jhep.2008.11.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  55 in total

1.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.

Authors:  Kui Li; Eileen Foy; Josephine C Ferreon; Mitsuyasu Nakamura; Allan C M Ferreon; Masanori Ikeda; Stuart C Ray; Michael Gale; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

2.  Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.

Authors:  Etienne Meylan; Joseph Curran; Kay Hofmann; Darius Moradpour; Marco Binder; Ralf Bartenschlager; Jürg Tschopp
Journal:  Nature       Date:  2005-09-21       Impact factor: 49.962

3.  Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

Authors:  Limin Chen; Ivan Borozan; Jordan Feld; Jing Sun; Laura-Lee Tannis; Catalina Coltescu; Jenny Heathcote; Aled M Edwards; Ian D McGilvray
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

4.  Hepatitis C virus expression suppresses interferon signaling by degrading STAT1.

Authors:  Wenyu Lin; Won Hyeok Choe; Yoichi Hiasa; Yoshitaka Kamegaya; Jason T Blackard; Emmett V Schmidt; Raymond T Chung
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

5.  Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.

Authors:  Johannes Wiegand; Peter Buggisch; Wulf Boecher; Stefan Zeuzem; Cornelia M Gelbmann; Thomas Berg; Wolfgang Kauffmann; Birgit Kallinowski; Markus Cornberg; Elmar Jaeckel; Heiner Wedemeyer; Michael P Manns
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

6.  Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.

Authors:  Koichi Watashi; Naoto Ishii; Makoto Hijikata; Daisuke Inoue; Takayuki Murata; Yusuke Miyanari; Kunitada Shimotohno
Journal:  Mol Cell       Date:  2005-07-01       Impact factor: 17.970

7.  Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.

Authors:  Sanaa M Kamal; Amr E Fouly; Refaat R Kamel; Bridgette Hockenjos; Ahmed Al Tawil; Khalifa E Khalifa; Qi He; Margaret J Koziel; Khairy M El Naggar; Jens Rasenack; Nezam H Afdhal
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682

8.  Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity.

Authors:  Xiao-Dong Li; Lijun Sun; Rashu B Seth; Gabriel Pineda; Zhijian J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-21       Impact factor: 11.205

9.  CD8 epitope escape and reversion in acute HCV infection.

Authors:  Joerg Timm; Georg M Lauer; Daniel G Kavanagh; Isabelle Sheridan; Arthur Y Kim; Michaela Lucas; Thillagavathie Pillay; Kei Ouchi; Laura L Reyor; Julian Schulze zur Wiesch; Rajesh T Gandhi; Raymond T Chung; Nina Bhardwaj; Paul Klenerman; Bruce D Walker; Todd M Allen
Journal:  J Exp Med       Date:  2004-12-20       Impact factor: 14.307

10.  Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication.

Authors:  Chunfu Wang; Michael Gale; Brian C Keller; Hua Huang; Michael S Brown; Joseph L Goldstein; Jin Ye
Journal:  Mol Cell       Date:  2005-05-13       Impact factor: 17.970

View more
  19 in total

1.  Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept.

Authors:  C Leboeuf; J Roser-Schilder; M Lambotin; S Durand; T Wu; C Fauvelle; B Su; E Bôle-Richard; M Deschamps; C Ferrand; P Tiberghien; P Pessaux; T F Baumert; E Robinet
Journal:  Gene Ther       Date:  2014-11-13       Impact factor: 5.250

2.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Authors:  Joachim Lupberger; Mirjam B Zeisel; Fei Xiao; Christine Thumann; Isabel Fofana; Laetitia Zona; Christopher Davis; Christopher J Mee; Marine Turek; Sebastian Gorke; Cathy Royer; Benoit Fischer; Muhammad N Zahid; Dimitri Lavillette; Judith Fresquet; François-Loïc Cosset; S Michael Rothenberg; Thomas Pietschmann; Arvind H Patel; Patrick Pessaux; Michel Doffoël; Wolfgang Raffelsberger; Olivier Poch; Jane A McKeating; Laurent Brino; Thomas F Baumert
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

3.  Predicting the probable outcome of treatment in HCV patients.

Authors:  Udayakumar Navaneethan; Nyingi Kemmer; Guy W Neff
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

4.  Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors.

Authors:  Swarna Mehrotra; Bhumika Sharma; Sonali Joshi; Barbara Kroczynska; Beata Majchrzak; Brady L Stein; Brandon McMahon; Jessica K Altman; Jonathan D Licht; Darren P Baker; Elizabeth A Eklund; Amittha Wickrema; Amit Verma; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2013-06-28       Impact factor: 5.157

5.  New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.

Authors:  Lucie Fénéant; Julie Potel; Catherine François; Famara Sané; Florian Douam; Sandrine Belouzard; Noémie Calland; Thibaut Vausselin; Yves Rouillé; Véronique Descamps; Thomas F Baumert; Gilles Duverlie; Dimitri Lavillette; Didier Hober; Jean Dubuisson; Czeslaw Wychowski; Laurence Cocquerel
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

6.  Analysis of mutations in the core and NS5A genes of hepatitis C virus in non-responder and relapser patients after treatment with Peg-IFN-α and ribavirin.

Authors:  Kattareeya Kumthip; Pattranuch Chusri; Chansom Pantip; Satawat Thongsawat; Amornrat O'Brien; Niwat Maneekarn
Journal:  Virusdisease       Date:  2016-01-18

7.  A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6.

Authors:  Xiao Liu; Xiaoqiong Duan; Jacinta A Holmes; Wenting Li; Sae Hwan Lee; Zeng Tu; Chuanlong Zhu; Shadi Salloum; Anna Lidofsky; Esperance A Schaefer; Dachuan Cai; Shilin Li; Haoju Wang; Yongfu Huang; Yongju Zhao; Ming-Lung Yu; Zhiwen Xu; Limin Chen; Jian Hong; Wenyu Lin; Raymond T Chung
Journal:  Hepatology       Date:  2019-02-13       Impact factor: 17.425

Review 8.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

Review 9.  Viral hepatocarcinogenesis.

Authors:  W-L Tsai; R T Chung
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

10.  A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.

Authors:  Jorge Méndez-Navarro; Ruby A Chirino; Kathleen E Corey; Emmanuel C Gorospe; Hui Zheng; Segundo Morán; Jesus A Juarez; Raymond T Chung; Margarita Dehesa-Violante
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.